LIN vs MLYS · P/E 34, rev $18.07B vs $2.17B cap
Linde plc Ordinary Shares (LIN) versus Mineralys Therapeutics, Inc. Common Stock (MLYS) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
Latest reported LIN revenue for 2026-06-30 was $18.07B. Net income was $3.79B. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
MLYS does not have a complete income-statement cache yet.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. MLYS currently screens at market cap $2.17B.
Not investment advice. Open the LIN and MLYS stock pages for the full models.
Not investment advice.